Peptide Compass · Research

BPC-157: human studies, side effects and supplier comparison

A BPC-157 listing is more than a number on a label. Start with a dated price sample, understand the research, and learn which documents matter when comparing suppliers.

Editorial expansion: 1 November 2026. Supplier records and prices retain their own dates; this is not a fresh audit of every listing.

BPC-157 human studies and side effects

A systematic review published in October 2026 searched for human evidence through 1 June 2026. It included three studies with 30 participants in total. The authors rated the evidence as very low certainty, citing weak methods, bias and imprecision. This broader review is distinct from the 2025 orthopaedic review described below, which used an earlier search cutoff.

Poolton, Minett & Kazmi (2026): systematic review

The included studies reported no treatment-related adverse events, but small studies cannot establish that adverse effects are absent. They provide little ability to detect rare events or to establish long-term safety. Reported symptom changes in uncontrolled studies are not proof of a treatment effect.

How much does BPC-157 cost?

BPC-157: price sample checked on 30 October 2026
VendorLabelled packListed pricePrice per mg¹Tax basis
Peptidwerk AdPartner10 mg34.95 EUR3.50 EURincl. 19% VAT
Particle Peptides AdPartner5 mg · Mannitol26.01 EUR5.20 EURnot established
Particle Peptides AdPartner10 mg · Mannitol47.15 EUR4.72 EURnot established
EuropaPeptide Ad10 mg35.90 EUR3.59 EURnot established

¹ Calculated from listed price and labelled amount, rounded to two decimal places. Excludes discount codes and shipping. Where tax treatment is unclear, final prices cannot be compared directly. Row order is not a price or quality ranking.

This sample covers four pack listings from three shops, not the entire market. Other portal tables retain their individually stated data dates. EuropaPeptide’s URL contains “5mg”, but the selected listing was labelled 10 mg. Always check the actual variant selected in the shop.

What is BPC-157 being studied for?

BPC-157 is a synthetic peptide investigated in preclinical models, including tissue processes. These models generate research questions. They do not by themselves establish benefits in humans or a reliable safety profile.

Predominantly preclinical

A 2025 systematic review of orthopaedic research included 36 studies: 35 preclinical and one clinical. Its search ended on 3 June 2024, so it is not a complete inventory of later research.

Small case series

Lee and Padgett’s 2021 paper was a retrospective analysis without a control group. It also included different treatment groups. It cannot establish a reliable treatment effect.

Unresolved safety questions

Small observations cannot reliably assess rare or long-term risks. A shop certificate does not answer these clinical questions either.

Which documents help you compare listings?

Check whether the laboratory report refers to the offered batch. Purity, identity testing and measured amount are different findings. A report showing only a purity percentage does not automatically establish how much BPC-157 is present in one vial.

Read a real COA step by step

BPC-157, TB-500 and the “Wolverine stack”

“Wolverine stack” is an online label for combinations marketed around BPC-157 and TB-500. The nickname is not a standardised clinical protocol or evidence that the combination is effective. A result from a single compound cannot establish the effect or safety of a combination.

The 2021 knee-pain report discussed below retrospectively described BPC-157 alone and alongside a thymosin-beta-4 product. That uncontrolled report does not establish a benefit from adding a second compound, nor does it verify that any shop product labelled TB-500 matches the studied material.

Lee & Padgett (2021): retrospective report

Common questions about BPC-157

What does “BPC-157 protocol” mean?

People often use “protocol” to mean a regimen. This page explains research rather than providing one. A regimen is not scientifically validated simply because it is widely shared online. The cited studies must be assessed by their design and limitations.

Is a larger pack automatically better value?

Price per mg only helps with arithmetic. Tax treatment, shipping, labelled amount, additives and matching batch documents still matter. Pack size is not a quality indicator.

Does “research use only” mean a product is proven safe?

No. The label describes the supplier’s stated intended use. It is not evidence of safety or suitability for human use.

Where to go next

Sources and review date

Sources for the new human-evidence and combination sections checked on 1 November 2026. The price sample and earlier document checks retain their 30 October 2026 dates. We did not collect or analyse shop samples.

  1. Vasireddi et al. (2025), systematic review
  2. Lee & Padgett (2021), retrospective case series
  3. Peptidwerk: BPC-157 10 mg Ad
  4. Particle Peptides: BPC-157 5 mg Ad
  5. Particle Peptides: BPC-157 10 mg Ad
  6. EuropaPeptide: selected BPC-157 listing Ad
  7. Poolton et al. (2026): human evidence, searched through June 2026

Created with AI assistance. This new edition has not yet received independent editorial review.